18.64
전일 마감가:
$18.30
열려 있는:
$18.06
하루 거래량:
842.41K
Relative Volume:
0.39
시가총액:
$3.45B
수익:
$1.03B
순이익/손실:
$-297.43M
주가수익비율:
-11.54
EPS:
-1.615
순현금흐름:
$-261.39M
1주 성능:
-2.66%
1개월 성능:
-2.66%
6개월 성능:
-42.18%
1년 성능:
-41.93%
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Compare LEGN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
LEGN
Legend Biotech Corp Adr
|
18.63 | 3.38B | 1.03B | -297.43M | -261.39M | -1.615 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.42 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.05 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
796.05 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.45 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.82 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-12 | 다운그레이드 | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-22 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2026-01-07 | 개시 | Oppenheimer | Outperform |
| 2025-10-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-06-17 | 개시 | Truist | Buy |
| 2024-05-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-05-23 | 개시 | Deutsche Bank | Buy |
| 2024-04-17 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | Raymond James | Outperform |
| 2023-12-19 | 개시 | Scotiabank | Sector Perform |
| 2023-11-06 | 개시 | Goldman | Buy |
| 2023-05-25 | 개시 | William Blair | Mkt Perform |
| 2023-05-22 | 개시 | Daiwa Securities | Buy |
| 2023-03-29 | 개시 | H.C. Wainwright | Buy |
| 2023-03-24 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-11-02 | 개시 | Evercore ISI | Outperform |
| 2022-11-01 | 개시 | Cowen | Outperform |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-03-15 | 개시 | Barclays | Overweight |
| 2022-01-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2020-07-01 | 개시 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Morgan Stanley | Overweight |
모두보기
Legend Biotech Corp Adr 주식(LEGN)의 최신 뉴스
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Legend Biotech (LEGN) Q2 2025 Earnings Transcript - The Globe and Mail
Legend Biotech Corporation Sponsored ADR $LEGN Shares Bought by SG Americas Securities LLC - MarketBeat
Legend Biotech (NASDAQ:LEGN) CEO Sells $87,138.72 in Stock - MarketBeat
Huang Ying, CEO of Legend Biotech, sells $87k in shares - Investing.com India
Recent Research Analysts’ Ratings Updates for Legend Biotech (LEGN) - Defense World
Virtus Biotech ETF Holdings - Quiver Quantitative
Hudson Bay Capital Management LP Has $7.17 Million Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Q1 EPS Estimate Decreased by HC Wainwright - MarketBeat
Q2 EPS Estimates for Legend Biotech Lowered by HC Wainwright - MarketBeat
Braidwell LP Decreases Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
ArrowMark Colorado Holdings LLC Cuts Position in Axis Capital Holdings Limited $AXS - Defense World
UiPath (NYSE:PATH) Price Target Cut to $13.00 by Analysts at Wells Fargo & Company - Defense World
Capital International Investors Sells 140,873 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
iShares MBS ETF $MBB Shares Acquired by Capital International Investors - Defense World
CLEAR Secure, Inc. (NYSE:YOU) Receives Average Recommendation of “Hold” from Analysts - Defense World
Royal Bank Of Canada Lowers Legend Biotech (NASDAQ:LEGN) Price Target to $62.00 - Defense World
Legend Biotech Plans to List in HK as Early as This Yr, Raising at Least US$300M: Wire - aastocks.com
RBC Capital lowers Legend Biotech stock price target on model updates By Investing.com - Investing.com South Africa
RBC Capital lowers Legend Biotech stock price target on model updates - Investing.com India
Legend Biotech Q4 2025 slides: CARVYKTI turns profitable, $555M sales By Investing.com - Investing.com South Africa
Raymond James reiterates Legend Biotech stock rating on strong Q4 results - Investing.com India
Truist reiterates Buy on Legend Biotech stock, $70 target on capacity - Investing.com
Jefferies reiterates Legend Biotech stock rating on Carvykti sales - Investing.com India
Jefferies reiterates Legend Biotech stock rating on Carvykti sales By Investing.com - Investing.com South Africa
Legend Biotech Q4 Earnings Call Highlights - Yahoo Finance
Legend Biotech Q4 2025 slides: CARVYKTI turns profitable, $555M sales - Investing.com India
Earnings call transcript: Legend Biotech Q4 2025 shows strong growth By Investing.com - Investing.com India
Earnings call transcript: Legend Biotech Q4 2025 shows strong growth - Investing.com
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Legend Biotech earnings on deck as profitability looms - Investing.com South Africa
Triata Capital Ltd Purchases 54,300 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Raymond James reiterates Legend Biotech stock rating after rival approval - Investing.com South Africa
Legend Biotech (NASDAQ:LEGN) Trading Up 5.5%Here's Why - MarketBeat
Artisan Partners Limited Partnership Purchases 425,684 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Westfield Capital Management Co. LP Lowers Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Nuclear Stocks To Research – February 23rd - Defense World
Raymond James reiterates Legend Biotech stock rating on valuation gap - Investing.com South Africa
Etsy (NYSE:ETSY) Stock Price Up 6.6% on Earnings Beat - Defense World
Barclays Cite Favorable Long-Term Outlook For Legend Biotech Corporation (LEGN) Despite Near-Term Expectation Revisions - Finviz
FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN) - Finviz
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Legend Biotech (NASDAQ:LEGN) Downgraded by Rothschild & Co Redburn to “Neutral” - Defense World
Legend Biotech stock rating downgraded by Rothschild Redburn on competition concerns By Investing.com - Investing.com India
Legend Biotech stock rating downgraded by Rothschild Redburn on competition concerns - Investing.com
Legend Biotech (NASDAQ:LEGN) Makes Strides in Nasdaq Composite Biotech Field - Kalkine Media
Investment Analysts’ Weekly Ratings Updates for Legend Biotech (LEGN) - Defense World
Legend Biotech (LEGN) Shakes Up Board - Finviz
Legend Biotech Corp Adr (LEGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):